Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte to consolidate two of its lines of shares

Thu, 13th May 2021 11:22

(Sharecast News) - Cell engineering company MaxCyte announced the consolidation of two of its lines of common stock into a single unrestricted line of common stock on Thursday.
The AIM-traded firm said it would be effected by the transfer of all stock comprising the Regulation S restricted trading line 'MXCL', to the unrestricted common stock trading line 'MXCT'.

It had previously said it intended the two lines of common stock to be consolidated following expiration of the distribution compliance period in relation to new shares on 22 May 2020.

The consolidation was intended to help both trading liquidity and transparency for shareholders, and would result in the cancellation of trading of the Regulation S restricted trading line 'MXCL'.

Currently, MaxCyte common stock is held as unrestricted stock trading under the symbol 'MXCT', and restricted stock trading under the symbols 'MXCL' and 'MXCN'.

The number of unrestricted shares of common stock trading under 'MXCT' is 74,454,534, while there are 9,900,089 restricted shares under 'MXCL' and 330,000 restricted shares under 'MXCN'.

"The consolidation will have a record date of 21 May and will be effective from 24 May, following which 84,354,623 MaxCyte common stock will be held as unrestricted shares in 'MXCT'," the board said in its statement.

"The number of restricted shares of common stock trading under the symbol MXCN will remain as 330,000 for the remainder of the applicable distribution compliance period."

At 1104 BST, shares in MaxCyte were up 0.06% at 892.5p.
More News
1 Aug 2023 14:26

TRADING UPDATES: MaxCyte strikes deal; Barkby sells Workshop

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
10 Jul 2023 14:05

MaxCyte inks deal with Vittoria Therapeutics for cellular therapies

(Alliance News) - MaxCyte Inc on Monday said it signed a strategic platform licence with Vittoria Biotherapeutics to advance cellular therapies.

Read more
10 Jul 2023 13:20

MaxCyte signs licence deal with Vittoria Biotherapeutics

(Sharecast News) - MaxCyte announced a strategic platform licence agreement with Vittoria Biotherapeutics on Monday, granting Vittoria non-exclusive clinical and commercial rights to use MaxCyte's 'Flow Electroporation' technology and 'ExPERT' platform.

Read more
6 Jul 2023 14:49

MaxCyte inks platform licensing deal with Lyell

(Sharecast News) - Cell engineering platform technology company MaxCyte announced a strategic platform licence (SPL) agreement with Lyell Immunopharma - a clinical-stage T-cell reprogramming company - on Thursday.

Read more
6 Jul 2023 13:58

MaxCyte inks strategic platform license with Lyell Immunopharma

(Alliance News) - MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company.

Read more
11 May 2023 12:10

MaxCyte revises guidance after weaker first quarter

(Sharecast News) - Cell engineering specialist MaxCyte saw its shares slide on Thursday, after it updated its revenue guidance for the year on the back of its first quarter performance.

Read more
11 May 2023 10:26

MaxCyte revenue declines, operating loss widens as costs increase

(Alliance News) - MaxCyte Inc on Thursday reported a widened operating loss in the first quarter of 2023 as revenue fell and costs were higher.

Read more
4 May 2023 17:26

IN BRIEF: MaxCyte signs strategic platform license with Walking Fish

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is "rapidly advancing B cell-based therapeutics." Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.

Read more
3 May 2023 14:50

UK earnings, trading statements calendar - next 7 days

Thursday 4 May 
Apax Global Alpha LtdQ1 Results
BAE Systems PLCTrading Statement
Cardiff Property PLCHalf Year Results
Derwent London PLCTrading Statement
e-Therapeutics PLCFull Year Results
Glanbia PLCQ1 Results
IMI PLCTrading Statement
Mondi PLCTrading Statement
Morgan Sindall Group PLCTrading Statement
Next PLCTrading Statement
Rathbones Group PLCTrading Statement
Shell PLCQ1 Results
Spirent Communications PLCTrading Statement
Trainline PLCFull Year Results
Virgin Wines UK PLCHalf Year Results
Wheaton Precious MetalsQ1 Results
Friday 5 May 
Eqtec PLCFull Year Results
InterContinental Hotels Group PLCTrading Statement
International Consolidated Airlines Group SAQ1 Results
Monday 8 May 
no events scheduled 
Tuesday 9 May 
Kosmos Energy LtdQ1 Results
Tialis Essential IT PLCFull Year Results
Treatt PLCHalf Year Results
Wednesday 10 May 
Anexo Group PLCFull Year Results
Asos PLCHalf Year Results
Compass Group PLCHalf Year Results
Directa Plus PLCFull Year Results
Georgia Capital PLCQ1 Results
MaxCyte IncQ1 Results
Spirax-Sarco Engineering PLCTrading Statement
Valeura Energy IncQ1 Results
Vertu Motors PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
30 Mar 2023 16:03

IN BRIEF: MaxCyte Chair Richard Douglas buys USD350,000 in shares

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has 100,000 shares, a 0.1% stake.

Read more
28 Mar 2023 13:03

MaxCyte installs Douglas Swirsky as its new finance chief

(Sharecast News) - Cell engineering technology company MaxCyte announced the appointment of Douglas Swirsky as its new chief financial officer on Tuesday.

Read more
28 Mar 2023 10:44

MaxCyte appoints new chief financial officer, effective immediately

(Alliance News) - MaxCyte Inc on Tuesday said it appointed Douglas Swirsky as its new chief financial officer, effective immediately.

Read more
16 Mar 2023 15:01

MaxCyte expecting strong 2023 after decent results

(Sharecast News) - Cell engineering specialist MaxCyte reported total revenue of $12.4m in the fourth quarter of 2022 on Thursday, making for an increase of 22% year-on-year.

Read more
16 Mar 2023 12:20

MaxCyte revenue up as growth expected in 2023; net loss widens

(Alliance News) - MaxCyte Inc on Thursday said revenue was up by a third in 2022, as it expects further growth in 2023.

Read more
8 Mar 2023 18:14

IN BRIEF: MaxCyte names members of new scientific advisory board

MaxCyte Inc - Maryland, US-based cell-engineering focused company - Forms new scientific advisory board that will reflect on research in molecular design and cell engineering and gain an understanding of translational development, in order to leverage the benefits of impactful discoveries for therapeutic applications. Board will include scientists, Oliver Rando, Marcela Maus, Avery Posey and Nako Nakatsuka.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.